Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Phase 1

• Conditions: B Cell Leukemia; Relapsed Adult ALL
• Interventions: Biological: anti-CD19 allo-CAR-T cells

• Registration Number: NCT04516551
• Lead Sponsor: Xinqiao Hospital of Chongqing

Brief Summary

The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after transplantation. Nowadays there is no effective way to salvage patients in such conditions. T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability, which makes it serve well for patients with relapsed B-ALL. So we launched a multi-center clinical trial to proved the safety and efficacy of anti-CD19 CAR-T cells for relapsed B cell ALL.

Detailed Description

The stunning response rate of anti-CD19(cluster of differentiation antigen 19) auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or refractory B-cell hematologic malignancies. However, for B-ALL patients suffered from relapse after allo-HSCT (hematopoietic stem cell transplant), the T cells derived from healthy donor seems like a better origin for CAR-T cells producing because T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability. So after we designed a clinical trial to manifest the safety and efficacy of anti-CD19 CAR-T cells for patients with relapsed B cell ALL.

Study Timeline

• Study First Submitted: 2020-08-13
• Study First Submitted QC: 2020-08-15
• Study First Posted: 2020-08-18
• Status Verified: 2020-11
• Last Update Submitted: 2020-11-12
• Last Update Posted: 2020-11-17
• Study Start: 2020-11-20
• Primary Completion: 2021-12-01
• Study Completion: 2022-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. Diagnosis of relapsed B-cell acute lymphoblastic leukemia (B-ALL).
2. Patients have received hematologic stem cell transplantation from matching sibling donor or unrelated donor.
3. CD19-positive tumor (>20% CD19 positive blasts by flow cytometry or immunohistochemistry (tissue)）
4. Hgb ≥ 7.0 (can be transfused)
5. Life expectancy greater than 12 weeks
6. Informed consent explained to, understood by and signed by the patient/guardian. The patient/guardian is given a copy of informed consent.

Exclusion Criteria

1. Other tumors except cured non-melanoma skin cancer, cervical cancer in situ, superficial bladder cancer, breast duct cancer in situ, or other malignant tumors with complete remission of more than 5 years)；
2. Severe mental disorders；
3. A history of genetic diseases such as Fanconi anemia, Shudder-Dale syndrome, Costman syndrome, or any other known bone marrow failure syndrome；
4. Subjects with II-IV grade acute graft versus host disease GVHD (Glucksberg Standrad) or chronic GVHD.
5. Heart disease with grade III-IV heart failure [NYHA classification], myocardial infarction, angioplasty or stenting, unstable angina or other heart diseases with prominent clinical symptoms within one year before admission；
6. Subjects with any indwelling catheter or drainage tube (such as percutaneous nephrostomy tube, bile drainage tube or pleura/peritoneum/pericardium catheter), should be excluded. (Special central venous catheter is allowed)；
7. Subjects with a history of CNS lymphoma, CSF malignant cells, or brain metastasis；
8. Subjects with a history of CNS disease,such as epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS；
9. Any of the following virological ELISA results are positive: HIV antibody, HCV antibody, TPPA, HBsAg；
10. Active infection requiring systematic treatment within 2 weeks before single collection；
11. Subjects with known severe allergic reactions to cyclophosphamide or fludarabine, or diagnosed as the allergy；
12. History of autoimmune diseases (e.g. Crohn disease, rheumatoid arthritis, systemic lupus erythematosus) that cause end-organ damage or require systemic immunosuppressive medications or systemic disease modifying drugs in the past 2 years；
13. Presence of pulmonary fibrosis；
14. Subjects who have received other clinical trial treatment within 4 weeks before participating in this trial should be excluded. Or the signing date of informed consent is within 5 half-lives of the last application of another clinical trial (whichever is longer)；
15. Subjects with poor compliance due to physiological, family, social, geographical and other factors, or those unable to cooperate with the study plan or follow-up；
16. At the discretion of the investigator, there are complications requiring systemic corticosteroid therapy (≥ 5mg / day of prednisone or equivalent dose of other corticosteroids) or other immunosuppressive drugs within 6 months after this clinical research treatment；
17. The lactating woman who is reluctant to stop breastfeeding；
18. Any other condition considered unsuitable by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
anti-CD19 allo-CAR-T	anti-CD19 allo-CAR-T cells	The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the "3 + 3" dose-escalation strategy to find MTD followed by a dose-expansion phase at determining optimal dosage. dosage: the number of anti CD19+CD22 CAR T cells -1(if needed) 1×10\^6/KG 3×10\^6 /KG 6×10\^6 /KG 1×10\^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days or bendamustione (90mg/m2 per day) for two days prior to cell infusion.

Primary Outcome Measures

Name	Time	Method
the safety of anti-CD19 allo CAR-T cells	within 4 weeks after infusion	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
the efficacy of anti-CD19 allo CAR-T cells	4 weeks after infusion	ratio of bone marrow blast cells

Secondary Outcome Measures

Name	Time	Method
The long-term efficiency	up to 2 years after infusion	ratio of bone marrow blast cells

Trial Locations

Locations (1)

Department of Hematology, Xinqiao Hospital; 🇨🇳 Chongqing, Chongqing, China